BioNTech Taps Oncology Heavyweights to Board as ASCO Data Looms Over Stock

BioNTech presents three ADCs and lung cancer data at ASCO; analysts split on pipeline potential. Company holds €16.8B cash but net loss widens.

Just days before the American Society of Clinical Oncology’s annual meeting kicks off in Chicago, BioNTech has strengthened its corporate oversight with two new board members who bring deep cancer experience. The move signals the Mainz-based company’s determination to execute a transformation from pandemic-era vaccine champion to a multi-product oncology powerhouse. Beginning May 29, however, the market will demand concrete evidence that the pipeline can deliver.

The centerpiece of the company’s ASCO presentations is a trio of antibody-drug conjugates. BioNTech will unveil data on BNT326/YL202 targeting HER3, BNT324/DB-1311 aimed at B7H3 in metastatic castration-resistant prostate cancer, and Trastuzumab Pamirtecan for recurrent endometrial carcinoma. The last of these already carries positive momentum: a primary analysis of a Phase 2 cohort in HER2-positive endometrial cancer yielded encouraging results, and additional updates are expected in Chicago. Four poster presentations on ongoing studies will round out the ADC programme. Alongside these, BioNTech will offer interim results from the Phase 2/3 study of Pumitamig in lung cancer, the asset many view as its most critical experimental therapy. Overlapping with that will be survival data on Gotistobart, a candidate being tested in platinum-resistant ovarian cancer.

Not everyone is convinced the pipeline can live up to market expectations. Bernstein analyst Jeffrey Walch initiated coverage with a “Market Perform” rating and a $96 price target, arguing that peak sales across the entire portfolio could come in 43% below consensus. He described the prevailing assumptions about success rates and market share as overly optimistic, particularly for Pumitamig. That scepticism stands in contrast to the ratings from Deutsche Bank, Goldman Sachs, and Jefferies, all of which retain buy calls. HC Wainwright is even more bullish, with a $130 target. The stock itself has been choppy: shares closed on Monday at €79.80, up 5.42% over the past week but down 10.03% on a monthly basis. The price sits 7.63% below its 200-day moving average, though the relative strength index at 61.6 hints at a recent recovery. Since the start of the year, the equity has lost roughly 4%.

Financially, BioNTech has the firepower to weather setbacks. The company closed the first quarter with €16.8 billion in cash and virtually no debt, according to the primary article’s data. A secondary source places the cash position at $19.6 billion, reflecting different reporting currencies or cut-off dates. Full-year revenue guidance stands at $2.3 billion to $2.6 billion. Management has authorised a share buyback of up to $1 billion over the next twelve months, aimed at signalling capital discipline. Yet the cost of expanding the oncology footprint remains steep: the net loss widened to $622.3 million in the recent quarter, while research and development spending hit $651.6 million, driven by programmes such as Pumitamig, Gotistobart, and investments in BioNTech China and CureVac.

The pipeline itself is broadening rapidly. BioNTech is now running more than 25 clinical trials in advanced stages, including 13 pivotal studies. Six more registrational trials are planned for the current year, potentially pushing the total number of Phase 3 programmes to 15, with seven late-stage data readouts on the horizon. For Pumitamig in particular, five new pivotal studies have already started, targeting breast, colorectal, gastric, and two lung cancer settings. Interim results from those are due later this year.

With the board now expanded from six to eight members following the election of Prof. Iris Löw-Friedrich and Susanne Schaffert—both seasoned in oncology, clinical development, and commercialisation—the company has reinforced its strategic direction. BioNTech’s goal is to have multiple approved products on the market by 2030. Whether that ambition gains or loses credibility will depend heavily on the data released from Friday onward. Strong ADC and bispecific signals could silence the doubters; any weakness or ambiguity would intensify the pressure on the later-stage pipeline.